Research Article

Crystalline Ultrastructures, Inflammatory Elements, and Neoangiogenesis Are Present in Inconspicuous Aortic Valve Tissue

P. Dorfmüller, D. Bazin, S. Aubert, R. Weil, F. Brisset, M. Daudon, F. Capron, and I. Brochériou

1 Service d’Anatomie et de Cytologie Pathologiques, Hôpital de la Pitié-Salpêtrière, 47-80 Boulevard de l’Hôpital, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, 75013 Paris, France
2 Service d’Anatomie et de Cytologie Pathologiques, Hôpital Marie Lannelongue, Université Paris-Sud, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France
3 Laboratoire de Physique des Solides, UMR 8502, Université Paris-Sud Orsay, Bâtiment 510, 91405 Orsay, France
4 Service de Chirurgie Cardiaque, Hôpital de la Pitié-Salpêtrière, 47-80 Boulevard de l’Hôpital, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, 75013 Paris, France

Correspondence should be addressed to P. Dorfmüller, peter.dorfmuller@u-psud.fr

Received 1 September 2010; Accepted 25 November 2010

Academic Editor: Gerald Maurer

Copyright © 2010 P. Dorfmüller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Morbidity from calcific aortic valve disease (CAVD) is increasing. Recent studies suggest early reversible changes involving inflammation and neoangiogenesis. We hypothesized that microcalcifications, chemokines, and growth factors are present in unaffected regions of calcific aortic valves. We studied aortic valves from 4 patients with CAVD and from 1 control, using immunohistochemistry, scanning electron microscopy, and infrared spectrography. We revealed clusters of capillary neovessels in calcified (ECC), to a lesser extent in noncalcified (ECN) areas. Endothelial cells proved constant expression of SDF-1 in ECC, ECN, and endothelial cells from valvular surface (ECS). Its receptor CXCR4 was expressed in ECC. IL-6 expression correlated with CXCR4 staining and presence of lymphocytes. VEGF was expressed by ECS, its receptor by ECC and ECN. Crystalline ultrastructures were found on the surface of histologically noncalcified areas (HNCAs), spectrography revealed calcium hydroxyapatite. Our results demonstrate that crystalline ultrastructures are present in HNCAs, undergoing neoangiogenesis in an inflammatory context. These alterations could be an early witness of disease and an opening to therapy.

1. Introduction

Calcific aortic valve disease (CAVD) is the most common valvular lesion in Western countries and the major cause of aortic valve replacement. It is associated with a higher death risk from cardiovascular causes which is increased up to 50 per cent, even in the absence of a hemodynamically significant obstruction [1, 2]. With an aging population, CAVD is becoming an important public health problem. Hitherto, a cure for symptomatic calcific aortic valve disease relies entirely within surgical procedures with valve replacement. Until recently, the concept that CAVD is a degenerative and unmodifiable process basically induced by long-lasting mechanical stress was generally accepted [3, 4]. Interestingly recent studies suggest that valvular changes might not be an unmodifiable degenerative disease but rather a dynamic process involving inflammation, lipid infiltration, dystrophic calcification, and endothelial dysfunction [5–7].

Chemokines and growth factors play an important role in several pathophysiological processes such as inflammation and immunity. Chemokine receptor CXCR4 is expressed on monocytes, B-lymphocytes, and most T cells [8–10]. It has been determined that CXCR4, which is present on many different types of cells, is activated by only one ligand, stromal derived factor 1 (SDF-1) and mediates several different activities such as chemotaxis, adhesion, proliferation,
survival, and, in some cells, apoptosis [11–13]. Activation of CXCR4 on lymphocytes and monocytes stimulates chemotaxis, resulting in recruitment to sites of immune and inflammatory reactions. Hematopoietic and endothelial progenitor cells express CXCR4, and release of SDF-1 by bone marrow stromal cells mediates sequestration and homing of these progenitor cells to the bone marrow [14, 15]. Vice versa, SDF-1 has also been implicated in revascularization of ischemic hind limbs through recruitment of CXCR4+ hematangiocytes [16, 17], and, recently, SDF-1 and its receptor CXCR4 have been shown to support development of vascular blood supply within inflammatory atherosclerotic plaques [18]. On the other hand some vascular growth factors, in particular VEGF and its receptors (VEGFR1 and 2), are known to be involved in the evolution of malignancies, intraocular neovascular disorders, and atherosclerotic plaque formation [19]. Pathological neoangiogenesis—whether in the context of inflammation or cancer—is partly put onto the account of VEGF/VEGFR signalling [20]. We hypothesized that SDF-1 and VEGF might act as regulators of angiogenesis within primarily concerned valves, depending on their expression and presence of their corresponding receptors on endothelial cells.

Due to routine experience with minimal valvular alterations including discrete calcification and associated capillary-like neovessels, we have been interested in possible early stage changes of clinically silent and macroscopically inconspicuous valve areas/valves. We therefore hypothesized that early fibrous remodeling and neoangiogenesis within aortic valves could be initiated by ultrastructural calcific alterations.

2. Methods

Tissue samples corresponding to aortic valve resections were collected from patients undergoing surgical treatment for CAVD (n = 4) and aortic insufficiency due to aortic arch aneurysms (n = 1) in the Department of Cardiac Surgery (Hôpital de la Pitié-Salpêtrière, Paris). After resection, specimens were fixed in formalin and dissected. Half of the specimens were processed for histology, embedding or complete negative. IL-6 was expressed in EC of all samples and from all anatomical compartments expressed vWF and CXCL12. CXCR4 expression was considered as nonvascularized tissues, few capillary neovessels, but no inflammatory infiltrates, were present on the control sample. Calcifications or major fibrous remodeling were not observed.

3. Results

3.1. Histopathology. The morphologic hallmarks of CAVD were heaped-up calcified masses within the aortic cusps that protruded into the outflow surfaces. Calcific deposits distorted the cuspal architecture, primarily at the bases. The free cuspal edges were usually not involved. On the leaflet profile calcifications were located within the valvular fibrosa, at the point of maximal cusp flexion. Cusps were heavily fibrosed and frequently presented chronic inflammatory infiltrate mainly consisting of lymphocytes, macrophages, and masts cells. Sporadically, foreign body granulomas with giant cells were present near calcifications. Numerous blood microves- sels within calcified areas were observed in close association to inflammatory infiltrates and frequently disposed in a nest-like pattern (Figure I(a)). Microvessels revealed different phenotypes with thin-walled capillary-like appearance or thickened arteriolar wall structure. Intra- or extracellular lipid depositions, as seen in arterial atheromatous lesions, were not observed. The histological valve architecture distant to calcified areas was preserved. Histomorphological correlates to calcification or microcalcification at this site were not observed. However, cusps showed some fibrous remodelling, and few thin-walled capillary neovessels were present. The control sample (Bentall surgery) grossly corresponded to a normal valve leaflet anatomy with a single layer of endothelial cells lining the spongiosa layer on the aortic side with loosely organized connective tissue and an elastin-rich ventricularis layer on the ventricular side. Although aortic valves are considered as nonvascularized tissues, few capillary neovessels, but no inflammatory infiltrates, were present on the control sample. Calcifications or major fibrous remodeling were not observed.

3.2. Immunohistochemistry. EC from all samples and from all compartments expressed vWF and CXCL12. CXCR4 expression was observed in ECC, while ECN and ECS were sporadically stained or completely negative. IL-6 was expressed in ECC and ECS, while mostly negative in ECN. The control sample presented with a different expression profile: as by definition, only ECN and ECS were present; while both...
Figure 1: Immunohistochemical pattern of inflammatory infiltrate and neovascular endothelial cells in microscopically calcified (ECC) and noncalcified (ECN) areas, as well as of surface endothelial cells (ECS) in aortic valves from patients with calcific aortic stenosis. (a) Hematoxylin-Eosin-Saffron staining, note multiple capillary neovessels near calcified area (arrows); (b) CD3+ lymphocytes in the range of neovessels (asterisks) near calcific lesions; (c) CD117+ cells corresponding to mast cells are sparsely present. (d) Neovessels of all subgroups are highlighted by FVIII staining (here: ECC) (e) CXCL12 (ECC); (f) CXCL12 (ECN); (g) CXCR4 (ECC); (h) CXCR4 (ECN); (i) IL-6 (ECC); (j) VEGF in surface endothelial cells (arrows on ECS); (k) VEGFR (arrows on ECC); (l) VEGFR (arrows on ECN). Images (a),(d),(f),(g),(h),(i),(j), and (k): magnification ×100; images (b),(c),(e), and (l): magnification ×200.

EC subgroups were easily detected by vWF expression and stained for CXCL12, ECN were negative for IL-6, while ECS moderately stained.

VEGF was constantly expressed in ECS of all valves and, to a lesser extent, in ECC. VEGFR1 was expressed in both ECC and ECN, while ECS was negative. ECN in the control sample revealed expression of VEGFR1.

Inflammatory infiltrate in the range of neovessels mainly revealed CD3+ lymphocytes and CD117+ mast cells. In an attempt to differentiate mast-cells from CD117+ bone marrow-derived progenitor cells, slides were secondarily counter stained with Toluidine-Blue; CD117-positive/Toluidine-negative cells were not observed. Immunohistochemical results are presented in Figures 1(b)–1(l).
3.3. Scanning Electron Microscopy. Scanning Electron Microscopy (SEM) analysis of the leaflet surface within noncalcified areas revealed the presence of two types of three-dimensional crystal structures: we differentiated plate-like, faceted microrods which were vertically inserted into the endothelial surface, measuring approximately 10 μm. These heterogeneously distributed structures where associated with 5–8 μm large sphere- or nodule-like structures, focally covering the leaflet surface. The same ultrastructural modifications were—to a lesser extent—present in the control sample (Figures 2(a) and 2(b)). In contrast, calcified areas massively displayed large crystalline accumulations of 100 μm and more, extensively covering the analyzed valve areas.

3.4. EDX Analysis. X-ray fluorescence emission revealed a significant phosphor peak in calcified and a small elevation of phosphor in noncalcified areas. No calcium peak was noticeable for noncalcified areas, whereas present in calcified regions. Light elements, such as carbonate, oxygen, and sodium were present in both regions (Figure 3).

3.5. FT-IR Spectroscopy. Calcium apatite and amorphous carbonated calcium phosphate were the major components in grossly calcified areas. Inconspicuous areas with crystalline ultrastructures only contained calcium apatite. Approximately 80% of the material in grossly calcified areas corresponded to calcium apatite, and 10% of calcium apatite was found in grossly noncalcified areas. Calcium apatite was also present in the control sample (Bentall surgery). Higher amounts of triglycerides were retrieved within inconspicuous valve areas, as compared to calcific lesions (Table 1).

4. Discussion

In order to detect ultrastructural pathological transformations in valve structure, we analyzed noncalcified and calcified areas of human aortic valves which had been surgically removed due to symptomatic calcific stenosis, as well as one totally inconspicuous valve excised in the context of Bentall surgery in a patient with nonatherosclerotic aortic aneurysm. After histological study of the samples, we submitted them to scanning electron microscopic and Fourier transform— infrared spectroscopy in an attempt to eventually define an elementary profile indicating an initial change in structural organization, possibly preceding manifest remodeling.

Our scanning electron micrographs suggest that crystalline ultrastructures of different appearance are present on the surface of histologically inconspicuous valve tissue. SEM analysis allowed us to differentiate two types of crystalline ultrastructures, within noncalcified areas: we discriminated smaller, spherical, or nodule-like structures partly covering the surface and accumulations of larger, plate-like faceted microrods radially inserted into the valve leaflet. Our observations match with the ultrastructural aspect of the samples.
of typical biological apatites within calcified lesions of human aortic valves: a physochemical and ultrastructural study by Mikroulis and coworkers of native aortic valves and porcine aortic bioprostheses revealed two types of coexisting valve deposits, that is, large (>20 micrometers) and medium (5–20 micrometers) plate-like crystals as well as micro-crystalline (<5 micrometers) calcium phosphate mineral formations [22]. Their results suggest that the mineral salt of calcified valves is a mixture of calcium phosphate phases, such as dicalcium phosphate dihydrate (DCPD), octacalcium phosphate (OCP), and hydroxyapatite (HAP). DCPD and OCP are suggested to be precursor phases transformed to HAP by hydrolysis. Of importance, the authors found a lower value of the Ca/P molar ratio in the bioprostheses as compared with native valves. This difference was ascribed to a higher content of precursor phases, such as DCPD and OCP in bioprosthetic valves, subsequently transformed into HAP. In terms of ultrastructural morphology and chemical composition we have found resembling pattern within macroscopically inconspicuous valve areas. Noteworthy, Ca/P ratio was significantly lower in macroscopically inconspicuous valve areas. As stated above, our SEM analysis revealed presence of faceted crystalline microrods and layered micronodules on the leaflet surface. These structures morphologically displayed tight adherence to the endothelial surface and might in terms of flow dynamics represent a critical source of mechanical and/or oxidative stress through flow turbulences. In a recent study, Miller and coworkers have reported significantly increased oxidative stress and altered antioxidant mechanisms in stenotic aortic heart valves, as compared to normal heart valves [25]. Interestingly, they have differentiated calcified from noncalcified regions of stenotic valves and found significant dysregulation of antioxidant enzymes superoxide dismutase (SOD) 1 and 3 in noncalcified areas, suggesting that an impairment of SOD upregulating mechanisms could contribute in a tissue damaging increase of superoxide levels. Of note, endothelial injury is considered as an early event in the formation of a pathological calcification especially in the sponiosa layer on the aortic side of the valve [26–28]. Further, previous studies have reported endothelial cell dysfunction in apparently calcified aortic valves with deregulation of endothelial cell markers such as ICAM-1, VCAM-1, IL-6, and FVIII, suggesting that endothelial cell dysfunction might to some extent be present in early stages of disease evolution [29–32]. Interestingly, Ewence and coworkers report a potential greater risk for calcium phosphate micro- and nanoparticles in early stages of atherosclerosis as compared to larger, radiologically visible deposits in more advanced lesions through an effective induction of various inflammatory pathways [33] and it may be speculated that these inflammatory mediators are expressed in the presence of valvular submicroscopic calcifications. However, our immunohistochemical experiments revealed different EC phenotypes, depending on the valve area and its pathological remodeling: we observed constant SDF-1 expression in EC from every compartment in human calcified aortic valves. In contrast, its receptor CXCR4 was mainly expressed in microvessel accumulations near calcified nodules and to a lesser extent in leaflet lining endothelium. Staining was inversely correlating with the distance to calcified areas. Interestingly a similar pattern was observed
in the expression of the proinflammatory cytokine IL-6, with prominent staining in EC near grossly lesioned valve areas. It has been speculated that augmentation of CXCR4 signalling in blood vessels near calcifications induces proliferation of neovessels and promotes inflammatory cell recruitment from blood [13–17]. The interplay of chronic inflammation and tissue calcification has many similarities with atherosclerosis of systemic arteries: the appearance and role of neoangiogenesis in calcified atheromas have been largely described and are still controversially discussed by several groups [34–36]. The formation of neovessels within a primary inflammatory lesion is considered as an early event in CAVD and might contribute to lesion progression by direct homing of inflammatory cells towards a chemokine gradient [18, 37]. The pathomechanisms of endothelial cell recruitment and neovessel organization within primary lesions remain to be clarified. Some investigators have detected significant numbers of endothelial progenitor cells predominantly localized within the valvular fibrosa of calcified valves, suggesting that cells of extravascular origin contribute to aortic valve degeneration [38]. Others have suggested that recruitment of circulating progenitor cells at the site of injured tissues facilitates neovascularization through the VEGF/SDF-1 system, both potent angiogenic factors [39]. In fact, it has been shown that VEGF expression is increased in grossly calcified aortic valve tissue and associated with neovascularization, as well as with expression of bone substrate proteins, such as osteopontin and osteocalcin [33]. Our results confirm that VEGF is mainly expressed in endothelial cells of the leaflet surface. Importantly, we found that its receptor VEGFR1 is expressed in EC of neovessels near calcified areas, as well as in noncalcified areas, suggesting an ongoing angiogenic loop within macroscopically bland areas with ultrastructural crystalline deposits. Regarding the possible presence of progenitor cells, our immunohistochemical experiments identified only granulated CD117-positive cells being toluidine-positive, as well, and hence most probably corresponding to masts cells and not to progenitor cells. Nevertheless, manifest calcific valve remodeling could be initiated after a primary ultrastructural event, through triggering of inflammatory cascades orchestrated by cytokines, such as IL-6 and subsequent pathologic angiogenesis via paracrine activity of VEGF/SDF-1, finally rendering the lesion site “active.”

The mechanism of CAVD remains largely unknown compared to our understanding of the mechanisms underlying atherosclerotic diseases. We hypothesize that the SDF-1/CXCR4 and the VEGF/VEGFR system could have a pivotal role in the initiation and development of CAVD. Our observations demonstrate that expression of SDF-1 and its receptor CXCR4 is present in EC of pathologic microvessels. Moreover expression of CXCR4 appears to correlate with expression of IL-6, a cytokine with potent proinflammatory activity in context of inflammation. Further more, we show that a constant VEGF expression of leaflet surface ECs is associated with VEGFR1 expression of ECs within pathologic neovessels and that those neovessels are not exclusively confined to calcified areas with inflammatory infiltrate but—even if distributed in a sparse pattern—can be observed in noncalcified areas of diseased valves, as well as in non-symptomatic valves lacking obvious calcification in light-microscopy, but revealing endothelium-adherent crystalline ultrastructures in SEM and IR spectrography.

The development of new pharmacologic therapies for this disease requires a clearer understanding of the mechanisms of disease onset. Angiogenic factors and proinflammatory cytokines are present and could represent an early witness of subsequent inflammatory activity, finally leading to fibrous remodeling and symptomatic valvulopathy.

**Authors’ contribution**
P. Dorfmüller and D. Bazin equally contributed to this study.

**References**

[1] A. Farzaneh-Far, D. Proudfoot, C. Shanahan, and P. L. Weissberg, “Vascular and valvar calcification: recent advances,” Heart, vol. 85, no. 1, pp. 13–17, 2001.

[2] K. D. O’Brien, “Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more),” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1721–1728, 2006.

[3] Y. B. Li, C. L. Hu, J. Liu, Q. Z. Tang, and C. X. Huang, “Calcific aortic valve disease should not be considered as a degenerative disease anymore,” Medical Hypotheses, vol. 68, no. 6, pp. 1233–1235, 2007.

[4] R. Rosenhek, F. Rader, N. Loho et al., “Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis,” Circulation, vol. 110, no. 10, pp. 1291–1295, 2004.

[5] E. R. Mohler, F. Gannon, C. Reynolds, R. Zimmerman, M. G. Keane, and F. S. Kaplan, “Bone formation and inflammation in cardiac valves,” Circulation, vol. 103, no. 11, pp. 1522–1528, 2001.

[6] P. Sucosky, K. Balachandran, A. Elhammali, H. Jo, and A. P. Yoganathan, “Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-β1-dependent pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 2, pp. 254–260, 2009.

[7] D. Hakuno, N. Kimura, M. Yoshioka, and K. Fukuda, “Molecular mechanisms underlying the onset of degenerative aortic valve disease,” Journal of Molecular Medicine, vol. 87, no. 1, pp. 17–24, 2009.

[8] B. Federspiel, I. G. Melhado, A. M. V. Duncan et al., “Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen,” Genomics, vol. 16, no. 3, pp. 707–712, 1993.

[9] H. Nomura, B. W. Nielsen, and K. Matsushima, “Molecular cloning of cDNAs encoding a LDL7 receptor and putative leukocyte chemotactic peptide receptors,” International Immunology, vol. 5, no. 10, pp. 1239–1249, 1993.

[10] M. Loetscher, T. Geiser, T. O’Reilly, R. Zwahlen, M. Baggioni, and B. Moser, “Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes,” Journal of Biological Chemistry, vol. 269, no. 1, pp. 232–237, 1994.

[11] C. C. Bleul, M. Farzan, H. Choe et al., “The lymphocyte chemottractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,” Nature, vol. 382, no. 6594, pp. 829–833, 1996.
[12] E. Oberlin, A. Amara, F. Bachelerie et al., “The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1,” *Nature*, vol. 382, no. 6594, pp. 833–835, 1996.

[13] C. C. Bleul, R. C. Fuhlibreg, J. M. Casasnovas, A. Aiuti, and T. A. Springer, “A highly efficacious lymphocyte chemotactant, stromal cell-derived factor 1 (SDF-1),” *Journal of Experimental Medicine*, vol. 184, no. 3, pp. 1101–1109, 1996.

[14] A. Aiuti, I. J. Webb, C. Bleul, T. Springer, and J. C. Gutierrez-Ramos, “The chemokine SDF-1 is a chemotactant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood,” *Journal of Experimental Medicine*, vol. 185, no. 1, pp. 111–120, 1997.

[15] D. Y. Jo, S. Rafii, T. Hamada, and M. A. S. Moore, “Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1,” *Journal of Clinical Investigation*, vol. 105, no. 1, pp. 101–111, 2000.

[16] D. K. Jin, K. Shido, H. G. Kopp et al., “Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes,” *Nature Medicine*, vol. 12, no. 5, pp. 557–567, 2006.

[17] D. H. Walter, U. Rochwalsky, J. Reinhold et al., “Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 27, no. 2, pp. 275–282, 2007.

[18] A. Zernecke, E. Shagdarsuren, and C. Weber, “Chemokines in atherosclerosis an update,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 11, pp. 1897–1908, 2008.

[19] P. W. Holm, R. H. J. A. Slart, C. J. Zeebregts, J. L. Hillebrands, and R. A. Tio, “Atherosclerotic plaque development and instability: a dual role for VEGF,” *Annals of Medicine*, vol. 41, no. 4, pp. 257–264, 2009.

[20] N. Ferrara, H. P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” *Nature Medicine*, vol. 9, no. 6, pp. 669–676, 2003.

[21] L. Maurice-Estpe, P. Levillain, B. Lacour, and M. Daoudon, “Advantage of zero-crossing-point first-derivative spectrophotometry for the quantification of calcium oxalate crystalline phases by infrared spectrophotometry,” *Clinica Chimica Acta*, vol. 298, no. 1–2, pp. 1–11, 2000.

[22] D. Mikroulis, D. Mavrilas, J. Kapolos, P. G. Koutsoukos, and C. Lolas, “Physicochemical and microscopical study of calcific deposits from natural and bioprosthetic heart valves. Comparison and implications for mineralization mechanism,” *Journal of Materials Science: Materials in Medicine*, vol. 13, no. 9, pp. 885–889, 2002.

[23] H. Bunjes, F. Steiniger, and W. Richter, “Visualizing the structure of triglyceride nanoparticles in different crystal modifications,” *Langmuir*, vol. 23, no. 7, pp. 4005–4011, 2007.

[24] T. Unruh, K. Westesen, P. Bösecke, P. Lindner, and M. H. J. Koch, “Self-assembly of triglyceride nanocrystals in suspension,” *Langmuir*, vol. 18, no. 5, pp. 1796–1800, 2002.

[25] J. D. Miller, YI. Chu, R. M. Brooks, W. E. Richenbacher, R. Peña-Silva, and D. D. Heistad, “Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvar stenosis in humans,” *Journal of the American College of Cardiology*, vol. 52, no. 10, pp. 843–850, 2008.

[26] J. M. Hurle, E. Colvee, and M. A. Fernandez-Teran, “The surface anatomy of the human aortic valve as revealed by scanning electron microscopy,” *Anatomy and Embryology*, vol. 172, no. 1, pp. 61–67, 1985.

[27] J. M. Riddle, C. H. Wang, D. J. Magilligan, and P. D. Stein, “Scanning electron microscopy of surgically excised human mitral valves in patients over 45 years of age,” *American Journal of Cardiology*, vol. 63, no. 7, pp. 471–477, 1989.

[28] M. Mizraie, T. Meyer, P. Schwarz, S. Lotfi, A. Rastan, and F. Schöndube, “Ultrastructural alterations in acquired aortic and mitral valve disease as revealed by scanning and transmission electron microscopical investigations,” *Annals of Thoracic and Cardiovascular Surgery*, vol. 8, no. 1, pp. 24–30, 2002.

[29] E. R. Mohler, “Mechanisms of aortic valve calcification,” *American Journal of Cardiology*, vol. 94, no. 11, pp. 1396–1402, 2004.

[30] C. A. Simmons, G. R. Grant, E. Manduchi, and P. F. Davies, “Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves,” *Circulation Research*, vol. 96, no. 7, pp. 792–799, 2005.

[31] C. S. Fox, C. Y. Guo, M. G. Larson et al., “Relations of inflammation and novel risk factors to valvular calcification,” *American Journal of Cardiology*, vol. 97, no. 10, pp. 1502–1505, 2006.

[32] D. M. Shavelle, R. Katz, J. Takasu et al., “Soluble intercellular adhesion molecule-1 (sICAM-1) and aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis (MESA),” *Journal of Heart Valve Disease*, vol. 17, no. 4, pp. 388–395, 2008.

[33] A. E. Ewence, M. Boottman, H. L. Roderick et al., “Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization,” *Circulation Research*, vol. 103, no. 5, pp. e28–e34, 2008.

[34] N. M. Rajamannar, T. B. Nealis, M. Subramaniam et al., “Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation,” *Circulation*, vol. 111, no. 24, pp. 3296–3301, 2005.

[35] F. Chalajour, H. Treede, U. M. Gehling et al., “Identification and characterization of cells with high angiogenic potential and transitional phenotype in calcific aortic valve,” *Experimental Cell Research*, vol. 313, no. 11, pp. 2326–2335, 2007.

[36] F. Chalajour, H. Treede, A. Ebrahimnejad, H. Lauke, H. Reichenspurner, and S. Ergun, “Angiogenic activation of valvular endothelial cells in aortic valve stenosis,” *Experimental Cell Research*, vol. 298, no. 2, pp. 455–464, 2004.

[37] D. Hakuno, N. Kimura, M. Yoshioka, and K. Fukuda, “Cellular mechanisms underlying the onset of degenerative aortic valve disease,” *Journal of Molecular Medicine*, vol. 87, no. 1, pp. 17–24, 2009.

[38] D. Skowasch, S. Schrepf, N. Wernert et al., “Cells of primarily extravascular origin in degenerative aortic valves and bioprostheses,” *European Heart Journal*, vol. 26, no. 23, pp. 2576–2580, 2005.

[39] A. Wragg, J. A. Mellad, L. E. Beltran et al., “VEGFR1/CXCR4-positive progenitor cells modulate local inflammation and augment tissue perfusion by a SDF-1-dependent mechanism,” *Journal of Molecular Medicine*, vol. 86, no. 11, pp. 1221–1232, 2008.